4-1BB

Advertisement

cGxPJobs Banner

Leads Biolabs’ Opamtistomig Shows Strong NSCLC Response Ahead of WCLC 2026

NANJING, China, May 28, 2026 Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB...

By cGxPwire Editor
May 29, 2026

Read More

Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC

NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...

By cGxPwire Editor
May 19, 2026

Read More

Advertisement

cGxPJobs

Directory